BackBiodexa Pharmaceuticals Plc Overview

Biodexa Pharmaceuticals Plc Total Revenue

Biodexa Pharmaceuticals Plc's total revenue is $0, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

N/A

As of Dec 2025

Annual Revenue (TTM)

N/A

Trailing 12 months ending Dec 2025

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Biodexa Pharmaceuticals Plc (BDRX) FAQ

Biodexa Pharmaceuticals Plc posts a total revenue of $0 as of December 2025. That compares with $230K in the prior-year period — down 100.0% year over year. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Biodexa Pharmaceuticals Plc's total revenue was $230K. The latest reading is $0 — a 100.0% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a total revenue near $110B is typical. Biodexa Pharmaceuticals Plc's $0 is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Total Revenue is one piece of Biodexa Pharmaceuticals Plc's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BDRX's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Biodexa Pharmaceuticals Plc's other metric pages and overview cover the third.